Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in …
M Mikulska, C Sepulcri, C Dentone… - Clinical Infectious …, 2023 - academic.oup.com
Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in …
M Mikulska, C Sepulcri, C Dentone… - … publication of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed Severe Acute Respiratory Syndrome Coronavirus 2 infection in …
M Mikulska, C Sepulcri, C Dentone, F Magne… - 2023 - cabidigitallibrary.org
Background: Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in …
M Mikulska, C Sepulcri, C Dentone… - Clinical Infectious …, 2023 - academic.oup.com
Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in …
M Mikulska, C Sepulcri, C Dentone, F Magne… - Clinical Infectious …, 2023 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Severely immunocompromised patients are at risk for prolonged or relapsed Coronavirus …
Severely immunocompromised patients are at risk for prolonged or relapsed Coronavirus …